US Patent Issued to The University of Bristol, Syncona IP Holdco (3) on March 31 for "AAV gene therapy vector with podocyte-specific promoter" (British Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,167, issued on March 31, was assigned to The University of Bristol (Bristol, Great Britain) and Syncona IP Holdco (3) Ltd. (London).

"AAV gene therapy vector with podocyte-specific promoter" was invented by Dominic Schmidt (London), Valeryia Kuzmuk (London), Moin Saleem (Bristol, Great Britain) and Gavin Welsh (Bristol, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "A viral vector, wherein the viral vector comprises a COL4A3, COL4A4 or COL4A5 transgene."

The patent was filed on March 12, 2021, under Application No. 17/909,839.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi...